VergleichsstudieKohortenstudie
Comparative drug survival of biologic classes in psoriasis: a Japanese single-centre cohort study
European Journal of Dermatology · 2026
DOI: 10.1684/ejd.2026.5140 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Dermatology, 2026. Verfasst von Daisuke Watabe und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Dermatologic Agents.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
PsoriasisBiological ProductsDermatologic AgentsHumansFemaleJapanRetrospective StudiesMaleTumor Necrosis Factor-alphaInterleukin-23Interleukin-17Middle AgedAntibodies, MonoclonalUstekinumabAntibodies, Monoclonal, HumanizedProportional Hazards ModelsInfliximabAdultAdalimumabEtanerceptAgedEast Asian People
Stichwörter der Autor:innen
IL-23 inhibitorJapanese patientsbiologicsdrug survivalpsoriasis
Substanzen
Biological ProductsTumor Necrosis Factor-alphaInterleukin-23Interleukin-17Dermatologic AgentsAntibodies, MonoclonalUstekinumabAntibodies, Monoclonal, HumanizedInfliximabAdalimumab
Zitieren
APA
Watabe, D., Tsunoda, K., Hamabata, A., Goto, M., Yoshioka, W., & Amano, H. (2026). Comparative drug survival of biologic classes in psoriasis: a Japanese single-centre cohort study. European Journal of Dermatology. https://doi.org/10.1684/ejd.2026.5140
Vancouver
Watabe D, Tsunoda K, Hamabata A, Goto M, Yoshioka W, Amano H. Comparative drug survival of biologic classes in psoriasis: a Japanese single-centre cohort study. European Journal of Dermatology. 2026. doi:10.1684/ejd.2026.5140
BibTeX
@article{Watabe2026,
author = {Watabe, Daisuke and Tsunoda, Kanako and Hamabata, Akemi and Goto, Maki and Yoshioka, Wakako and Amano, Hiroo},
title = {Comparative drug survival of biologic classes in psoriasis: a Japanese single-centre cohort study},
journal = {European Journal of Dermatology},
year = {2026},
doi = {10.1684/ejd.2026.5140}
}
EUVIMED